Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Rhea-AI Summary

Relmada Therapeutics (NASDAQ:RLMD), a clinical-stage biotechnology company focused on oncology and central nervous system therapies, will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 PM ET to discuss Q2 2025 financial results and business updates.

The conference call will be accessible via US dial-in (1-877-407-0792) and International dial-in (1-201-689-8263) with conference code 13754263. A webcast replay will be available in the Investors section of Relmada's website.

News Market Reaction

-2.77%

1 alert

-2.77% News Effect

On the day this news was published, RLMD declined 2.77%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress.

Conference Call and Webcast Information:

• Date: Thursday, August 7, 2025 at 4:30 PM ET
• Participant Dial-in (US): 1-877-407-0792
• Participant Dial-in (International): 1-201-689-8263
• Conference: 13754263
• Webcast Access: Click Here
  

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

FAQ

When will Relmada Therapeutics (RLMD) report Q2 2025 earnings?

Relmada Therapeutics will report Q2 2025 earnings on Thursday, August 7, 2025 at 4:30 PM ET via conference call and webcast.

How can investors access Relmada's Q2 2025 earnings call?

Investors can access the call through US dial-in (1-877-407-0792), International dial-in (1-201-689-8263), or the webcast link available on Relmada's investor relations website.

What is Relmada Therapeutics' main business focus?

Relmada Therapeutics is a clinical-stage biotechnology company developing innovative therapies for oncology and central nervous system indications.

Where can investors find the replay of Relmada's Q2 2025 earnings call?

A replay of the webcast will be available in the Investors section of the Relmada website at www.relmada.com/investors/ir-calendar.